BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In the CML context, characterized by low genomic complexity and a single driver oncogene [19, 20], the pre-existence or the onset of a new genetic event, namely a BCR-ABL1 kinase domain mutation, provides a reproductive advantage during inhibitor treatment and may represent the first event driving the emergence of resistant clones.